Increase in Fibrinolytic Activity after Erythropoietin Therapy

• References

• 1 Casati C, Passerini P, Campise MR, Graziani G, Cesana B, Perisic M, Ponticelli C. Benefits and risks of protracted treatment with human recombinant erythropoietin in patients having haemodialysis. Br Med J 1987; 295: 1017-1020
• 2 Gordge MP, Leaker B, Patel A, Oviasu E, Cameron JS, Neild GH. Recombinant human erythropoietin shortens the uraemic bleeding time without causing intravascular haemostatis activation. Thromb Res 1990; 57: 171-182
• 3 Chmielewska JN, Wiman B. Determination of tissue plasminogen activator and its “fast” inhibitor in plasma. Clin Chem 1985; 32: 482-485